ClinicalTrials.Veeva

Menu

Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE

U

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

Enrolling

Conditions

Hepatocellular Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT07235410
[2025](1186)

Details and patient eligibility

About

Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients diagnosed with "Hepatocellular Carcinoma" from January 1, 2018 to May 31, 2024;
  2. Age > 18 years old.

Exclusion criteria

  1. Poor image quality;
  2. Loss of follow-up;
  3. Presence of another type of malignant tumor other than liver cancer;
  4. Incomplete medical records.

Trial contacts and locations

1

Loading...

Central trial contact

Yuanyuan Chu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems